BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li H, Kaiser TK, Borschiwer M, Bohnenberger H, Reichardt SD, Lühder F, Walter L, Dressel R, Meijsing SH, Reichardt HM. Glucocorticoid resistance of allogeneic T cells alters the gene expression profile in the inflamed small intestine of mice suffering from acute graft-versus-host disease. The Journal of Steroid Biochemistry and Molecular Biology 2019;195:105485. [DOI: 10.1016/j.jsbmb.2019.105485] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Kaiser TK, Li H, Roßmann L, Reichardt SD, Bohnenberger H, Feldmann C, Reichardt HM. Glucocorticoids delivered by inorganic-organic hybrid nanoparticles mitigate acute graft-versus-host disease and sustain graft-versus-leukemia activity. Eur J Immunol 2020;50:1220-33. [PMID: 32133644 DOI: 10.1002/eji.201948464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Reichardt SD, Amouret A, Muzzi C, Vettorazzi S, Tuckermann JP, Lühder F, Reichardt HM. The Role of Glucocorticoids in Inflammatory Diseases. Cells 2021;10:2921. [PMID: 34831143 DOI: 10.3390/cells10112921] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kaiser TK, Khorenko M, Moussavi A, Engelke M, Boretius S, Feldmann C, Reichardt HM. Highly selective organ distribution and cellular uptake of inorganic-organic hybrid nanoparticles customized for the targeted delivery of glucocorticoids. Journal of Controlled Release 2020;319:360-70. [DOI: 10.1016/j.jconrel.2020.01.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Toubai T, Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease. Blood 2020;136:429-40. [PMID: 32526035 DOI: 10.1182/blood.2019000953] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
5 Dou L, Peng B, Li X, Wang L, Jia M, Xu L, Li F, Liu D. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial. Trials 2022;23:470. [PMID: 35668528 DOI: 10.1186/s13063-022-06426-2] [Reference Citation Analysis]
6 Muzzi C, Watanabe N, Twomey E, Meers GK, Reichardt HM, Bohnenberger H, Reichardt SD. The Glucocorticoid Receptor in Intestinal Epithelial Cells Alleviates Colitis and Associated Colorectal Cancer in Mice. Cell Mol Gastroenterol Hepatol 2021;11:1505-18. [PMID: 33316454 DOI: 10.1016/j.jcmgh.2020.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Nieto Y, Ciurea SO, Oran B, Im J, Olson A, Marin D, Qazilbash M, Khouri I, Rondon G, Anderlini P, Rezvani K, Popat U, Kebriaei P, Shpall E, Champlin R, Alousi A. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther 2021;27:272.e1-5. [PMID: 33781539 DOI: 10.1016/j.jtct.2020.12.011] [Reference Citation Analysis]